Earnings Releases·Nov 4, 2026, 6:30 AM ET

Zimmer Biomet — Third Quarter 2026 Earnings Summary

Reported third-quarter net sales rose 3.1% to $2.063 billion, while diluted EPS declined 13.8% to $1.00; adjusted diluted EPS remained flat at $1.90, with strong operating cash flow of $560.0 million and free cash flow of $372.4 million.
Management raised full-year 2026 guidance across all metrics, increasing reported revenue growth expectations to 4.4%–4.9% and adjusted diluted EPS to $8.50–$8.60, citing broad-based performance and confidence in the outlook.
Strategic growth was driven by Hips (+6.0%) and S.E.T. (+6.8%) segments, while Knees sales declined 3.1%; the company also expanded its robotics portfolio via an agreement with THINK Surgical and launched new foot and ankle products.
Capital return initiatives included $139.2 million in dividends and $579.3 million in common stock repurchases during the first nine months of 2026, alongside the appointment of new executives to accelerate U.S. commercial transformation.